FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> Merck | Wyeth | Vioxx | lawsuits | lawsuit

Big Pharma balks at lawsuit rule

Tools

Fighting lawsuits is bad enough. After all, the pharma business is full of them: patent fights, product liability cases, regulatory disputes. Now, the Financial Accounting Standards Board--the accounting organization that sets the rules for companies' numbers-reporting--wants businesses to regularly disclose how much various lawsuits will cost them. Six Big Pharma companies--Johnson & Johnson, Novartis, Pfizer, Merck, Eli Lilly, and Wyeth--weighed in with a protest.

Estimating those costs is well nigh impossible, not to mention expensive, the companies contended in a letter to FASB. Examples? Take the fight over Merck's painkiller Vioxx. First, a Texas jury awarded one survivor more than $250 million, then a court struck the ruling down completely. Wyeth's fen-phen troubles are also an example. The company thought it might settle those claims for $3.75 billion, but instead has set aside or paid out more than $21 billion in legal fees, judgments and settlements. With numbers all over the map like that, how could estimates be valuable to investors, they argue. A former FASB chairman agrees; he told the Wall Street Journal, "I think the board has gone too far."

- read the WSJ story

More stories about Merck   Wyeth   Vioxx   lawsuits   lawsuit  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 31 + 4?
To combat spam, please solve the math question above.